Mycenax Biotech to Speak at PDA Advanced Parenteral Therapeutics & Quality Summit 2026
Mycenax Biotech is pleased to announce that Pang-Liang (Toby) Liu, Vice President of the Operation Center, will be presenting at the PDA Advanced Parenteral Therapeutics & Quality Summit 2026 in Taipei, Taiwan.
Session Details
-
Topic: Contamination Control Strategy (CCS) for Biologics Manufacturing: Regulatory Expectations and Critical Quality Considerations
-
Date & Time: September 22, 2026 | 11:40 – 12:10
-
Speaker: Pang-Liang (Toby) Liu, Vice President of Operation Center, Mycenax Biotech
Overview With updated regulatory standards such as EU GMP Annex 1, a Contamination Control Strategy (CCS) is a mandatory, facility-wide framework rooted in science and risk management. This session offers practical, regulator-aligned insights for biologics manufacturers, covering essential pillars including:
-
Regulatory expectations and quality system integration
-
Workstream, raw material, and facility controls (including barrier technologies)
-
Process, utilities, and environmental monitoring
-
Production configuration and lifecycle management
Connect with Mycenax The Mycenax team will also be exhibiting at the summit. We invite attendees and industry partners to visit our booth to discuss CDMO solutions and collaboration opportunities.
Mycenax Biotech to Speak at PDA Advanced Parenteral Therapeutics & Quality Summit 2026
Mycenax Biotech is pleased to announce that Pang-Liang (Toby) Liu, Vice President of the Operation Center, will be presenting at the PDA Advanced Parenteral Therapeutics & Quality Summit 2026 in Taipei, Taiwan.
Session Details
-
Topic: Contamination Control Strategy (CCS) for Biologics Manufacturing: Regulatory Expectations and Critical Quality Considerations
-
Date & Time: September 22, 2026 | 11:40 – 12:10
-
Speaker: Pang-Liang (Toby) Liu, Vice President of Operation Center, Mycenax Biotech
Overview With updated regulatory standards such as EU GMP Annex 1, a Contamination Control Strategy (CCS) is a mandatory, facility-wide framework rooted in science and risk management. This session offers practical, regulator-aligned insights for biologics manufacturers, covering essential pillars including:
-
Regulatory expectations and quality system integration
-
Workstream, raw material, and facility controls (including barrier technologies)
-
Process, utilities, and environmental monitoring
-
Production configuration and lifecycle management
Connect with Mycenax The Mycenax team will also be exhibiting at the summit. We invite attendees and industry partners to visit our booth to discuss CDMO solutions and collaboration opportunities.
